Results 241 to 250 of about 26,123,489 (353)

In Vivo CRISPR Screen Identifies RPS19 as an Immunotherapy Target in Hepatocellular Carcinoma

Advanced Science, EarlyView.
By employing in vivo CRISPR functional screening, we identify ribosomal protein RPS19 as a pivotal mediator driving immune evasion in hepatocellular carcinoma, wherein tumor‑released RPS19 binds C5aR1 on tumor‑associated macrophages to initiate downstream immunosuppressive signaling; SP94‑peptide‑modified SNPSS nanoparticles deliver Cas9/sgRPS19 ...
Lei He, Duo Yu, Fei Xie, Kaisheng Hou, Zhaozhao Li, Meifang Dai, Jingyi Yun, Haiyan Cao, Yang Xiao, Yueyuan Qiu, Gege Shi, Wangqian Zhang, Shuning Wang, Qiang Hao, Jieyu Zhang, Zhaowei Wang, Yingqi Zhang, Kuo Zhang, Jintao Gu, Haichen Du, Meng Li   +20 more
wiley   +1 more source

Sex Differences in Response to Viral Vector Vaccines-Implications for Future Vaccine Design. [PDF]

Immunol Rev
Grewe I, Zoran T, Addo MM.
europepmc   +1 more source

Combined Immune‐Peptide Nanofiber with HSP70/AKT/mTOR Axis Blockade Enhances Photothermal Immunotherapy, Inhibiting Tumor Growth and Recurrence

Advanced Science, EarlyView.
A carrier‐free peptide‐guided PSP@IR‐CF3 nanofiber system integrates PD‐L1 targeting and photothermal immunotherapy for enhanced cancer treatment. By revealing PTIT‐induced activation of the HSP70/AKT/mTOR pathway and incorporating mTOR inhibition, this strategy effectively overcomes therapeutic resistance and prevents tumor recurrence, providing a ...
Xinyu Zhang, Zhenqi Jiang, Wenjia Zhang, Juncheng Wu, Haozhuo Guo, Changlei Li, Mingwei Sun, Xiaoying Tang, Yue Zhang, Wei Huang, Huadan Xue, Yang Du   +11 more
wiley   +1 more source

Immunoinformatics driven multi-epitope vaccine design targeting clade IIb Mpox variant. [PDF]

Sci Rep
Tariq SS, Zia K, Ali N, Nur-E-Alam M, Ghayur MN, Aman A, Ul-Haq Z.   +6 more
europepmc   +1 more source

CircFAM65A/CANX Condensates Sequester FAM134B to Inhibit ER‐phagy and Suppress Hepatocellular Carcinoma Progression

Advanced Science, EarlyView.
The novel circRNA circFAM65A suppresses HCC progression. Mechanistically, circFAM65A drives CANX phase separation, which recruits FAM134B into condensates and blocks its interaction with LC3, thereby inhibiting ER‐phagy and HCC progression. Importantly, targeted circFAM65A delivery represents a potential therapeutic strategy for HCC.
Wenxiu Ru, Lunbiao Gan, Yu Lu, Yujing Guo, Qian Huang, Sha Yin, Fengze Nie, Sijia Di, Jiaqi Ning, Siyu Yao, Huanhuan Wan, Le Liu, Zehua Liu, Fa Yang, Weijun Qin, Weihong Wen   +15 more
wiley   +1 more source

Vaccine Design against <i>Fusobacterium nucleatum</i> FadA Protein in Periodontal Infections. [PDF]

Front Dent
Rathod NN, Jeevitha M, Yadalam PK, Raee A, Heboyan A.   +4 more
europepmc   +1 more source

A Bi‐Adjuvant Senolytic Nanovaccine Modulating Dendritic Cell Senescence Ameliorates Aging‐Related Metabolic Dysfunction

Advanced Science, EarlyView.
An active biomaterial‐based bi‐adjuvant nanovaccine restores the immunocompetence of aged dendritic cells to overcome senescent cell tolerance. Accompanied by the downregulation of mitotic kinases Aurka/b and attenuation of senescence‐associated PI3K/AKT phosphorylation, the nanovaccine enhances antigen‐presenting capacity and promotes potent cytotoxic
Qingxu Song, Xiaoxue Du, Wenbo Dong, Ying Wang, Xiaojing Wang, Qiliang Yin   +5 more
wiley   +1 more source

Editorial: Data-driven vaccine design for microbial-associated diseases. [PDF]

Front Immunol
Selvaraj G, Kaliamurthi S, Wei D.
europepmc   +1 more source

Topology‐Driven X‐Shaped DNA as a cGAS Stimulator to Promote Dendritic Cell Activation and Antitumor Vaccine Efficacy

Advanced Science, EarlyView.
X‐shaped DNA promotes multivalent cGAS assembly and enhances cGAS‐STING signaling. When conjugated with antigenic peptides, the resulting X‐DNA‐based peptide vaccine promotes dendritic cell activation, antigen presentation, and antitumor T‐cell responses.
Jiabei Li, Xuan Wang, Dali Wei, Zhejie Chen, Ziyi Wang, Qing Yu, Yu Yang, Shengpeng Wang   +7 more
wiley   +1 more source

Infusion of neutralization into Lassa vaccine design. [PDF]

Trends Immunol
Li H, Hastie KM, Saphire EO.
europepmc   +1 more source